Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer

30 Apr 2025

Abstract excerpt

Colorectal cancer (CRC) is one of the most common cancers worldwide, with KRAS mutations occurring in approximately 40% of cases. These mutations drive tumorigenesis through the constitutive activation of key signaling pathways, such as RAS-RAF-MEK-ERK (MAPK) and PI3K-AKT-mTOR, contributing to therapeutic resistance and poor prognosis. Advances in molecular biology have led to significant breakthroughs, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Colorectal Cancer Treatments and Studies
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40361439
DOI: 10.3390/cancers17091512

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the KRAS Oncogene for Patients with Metastatic Colorectal CancerPMID 40361439Read ↗

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Semantic proximity Read ↗

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic PerspectivesSemantic proximity Read ↗

Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.Semantic proximity Read ↗

Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions.Semantic proximity Read ↗

KRAS inhibition in metastatic colorectal cancer: An update.Semantic proximity Read ↗

Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer.Semantic proximity Read ↗

KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.Semantic proximity Read ↗

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.Semantic proximity Read ↗

Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine.Semantic proximity Read ↗

Targeting KRASG12C in colorectal cancer: the beginning of a new era.Semantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.